Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Neoplasms 1Advanced Solid Tumors 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × Cdc25C phosphatase (211-221) × Clear all
NCT03113188 2021-03-10

CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

CanBas Co. Ltd.

Phase 1 Completed
47 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT00551512 2017-03-14

Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors

CanBas Co. Ltd.

Phase 1 Completed
48 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡